Vimarsana
Biggest News Aggregation in the World

Page 3 - Daniel Alkon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Alkon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Alkon Today - Breaking & Trending Today

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease - Vimarsana News

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Published: April 5, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

Source: prnewswire.com
Related Topics:
Daniel AlkonRobert WeinsteinJarin HongpaisanGeorge PerryNational Institutes Of HealthDrug AdministrationSynaptogenix IncSemmes Distinguished UniversityExchange CommissionUniversity Of TexasKimmel Medical College Of Thomas Jefferson UniversityKimmel Medical CollegeThomas Jefferson UniversityChief Science OfficerScientific Advisory BoardSemmes Distinguished University ChairHealth Supported PhaseOrphan Drug DesignationMedia Contact
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit - Vimarsana News

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Published: March 29, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

Source: prnewswire.com
Related Topics:
Daniel AlkonHanson WadeRobert WeinsteinExchange CommissionNational Institute Of HealthDrug AdministrationNeurodegenerative Drug Development Summit OnNeurodegenerative Drug Development SummitSynaptogenix IncChief Scientific OfficerAnnual Neurodegenerative Drug Development SummitTargets RestorationSynaptic WiringAdvanced AlzheimerNational InstituteAnnual Neurodegenerative Drug DevelopmentOrphan Drug DesignationHealth Care Amp Hospitals Medical Pharmaceuticals Biotechnology Pharmaceuticals Trade Show News
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum - Vimarsana News

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Published: March 22, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

Source: prnewswire.com
Related Topics:
Daniel AlkonRobert WeinsteinExchange CommissionDrug AdministrationSachs ForumPrnewswire Synaptogenix IncSynaptogenix IncChief Scientific OfficerSynaptogenix PhaseSevere Impairment BatteryJournal AlzheimerOrphan Drug Designation
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) - Vimarsana News

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Published: March 15, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders,...

Source: prnewswire.com
Related Topics:
Daniel AlkonRobert WeinsteinExchange CommissionNational Institutes Of HealthDrug AdministrationInternational Conference On AlzheimerPrnewswire Synaptogenix IncSynaptogenix IncChief Scientific OfficerInternational ConferenceNational InstitutesMultiple SclerosisOrphan Drug DesignationHealth Care Amp Hospitals Medical Pharmaceuticals Biotechnology Pharmaceuticals Mental HealthClinical Trials Amp Medical Discoveries
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis - Vimarsana News

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Published: February 23, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...

Source: prnewswire.com
Related Topics:
Daniel AlkonRobert WeinsteinAlan TuchmanNemoursai DupontExchange CommissionDrug AdministrationSynaptogenix IncCleveland ClinicChief ScientificOrphan Drug DesignationPrivate Securities Litigation Reform ActAutistic Spectrum Disorder DeficitsMedia Contacts